IGC (IGC Pharma) Risk Assessment


IGC IGC Pharma Inc IGC
30 GF Score
Price $0.28
GF Value $0.24
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is IGC Pharma Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of IGC Pharma is: High Risk: High uncertainty with risk-return tradeoff.

IGC Pharma  (AMEX:IGC) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

IGC Pharma Risk Assessment Related Terms

IGC vs SER, NRSN, PVCT: Risk Assessment Comparison

For the Biotechnology subindustry, IGC Pharma's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IGC Pharma Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGC Pharma's Risk Assessment distribution charts can be found below:

* The bar in red indicates where IGC Pharma's Risk Assessment falls into.


IGC
30GF Score
IGC Pharma Inc IGC
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is IGC Pharma (IGC) Overvalued in 2026?

Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued. The current stock price of $0.28 is trading 16.3% above its estimated GF Value™ of $0.24. GuruFocus considers IGC Pharma to be Modestly Overvalued.

Key valuation signals for IGC:

  • Risk Assessment:
  • GF Value™: $0.24 vs. price of $0.28 (16.3% above fair value)
  • GF Score™: 30/100 with 6 warning signs

No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IGC Pharma Business Description

Other Exchanges IGS1:Germany
Address 10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
30GF Score

Get the complete analysis for IGC

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price
$0.24
GF Value